GTailor™

GTailor™

Design, Construction and Screening for Multiplex Therapeutic Transgenes

GenomeFrontier has established the GTailor™ platform to yield promising multiplex transgene candidates for development into advanced, affordable and efficacious gene-modified cell products and cell therapies. This platform supports identification and evaluation of multiplex transgene leads and candidates using a functional optimization strategy.

The GTailor™ platform is built from GenomeFrontier innovations and know-how:
(1) Proprietary therapeutic gene library
(2) Comprehensive virus-free genetic engineering toolbox
(3) Capabilities for efficiently generating innovative multiplex design constructs
(4) Capacity to establish and test libraries of therapeutic cells
(5) Diverse and comprehensive disease model systems for functional testing.

Within the GTailor™ platform, these technologies and capabilities synergistically facilitate the rapid identification of lead and candidate construct designs for clinical development (Figure 1).

Figure 1. Following the identificaiton of a suitable lead therapeutic with Protein/Target Hunter (e.g. tumor-targeting proteins and/or tumor microenvironment modulating proteins), the protein sequence is confirmed for accuracy and added to GenomeFrontier's library of therapeutic DNAs. The identified component is then incorporated into various multiplex transgenes, which are constructed in GenomeFrontier's virus-free gene transfer system. The lead transgenes are functionally evaluated and compared using in vitro and in vivo model systems best suited for the intended usage. The process is repeated until an appropriate candidate for clinical development is identified.

By focusing the evaluation of components and transgene configurations on the final product, use of the GTailor™ platform ensures that transgene design will yield highly desirable and consistent cell attributes. The evaluation endpoints will differ for each desired application; however, the process remains the same. GenomeFrontier has access to extensive laboratory models for evaluation fo gene modified cell therapies in different disease states.